Supramolecular Nanofibers of Drug‐Peptide Amphiphile and Affibody Suppress HER2+ Tumor Growth
Antibody‐based medicines and nanomedicines are very promising for cancer therapy due to the high specificity and efficacy of antibodies. However, antibody‐drug conjugates and antibody‐modified nanomaterials frequently suffer from low drug loading and loss of functions due to the covalent modificatio...
Gespeichert in:
| Veröffentlicht in: | Advanced healthcare materials 2018-11, Vol.7 (22), p.e1800899-n/a |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 22 |
| container_start_page | e1800899 |
| container_title | Advanced healthcare materials |
| container_volume | 7 |
| creator | Liang, Chunhui Zhang, Lushuai Zhao, Wene Xu, Linlin Chen, Yaoxia Long, Jiafu Wang, Fuqiang Wang, Ling Yang, Zhimou |
| description | Antibody‐based medicines and nanomedicines are very promising for cancer therapy due to the high specificity and efficacy of antibodies. However, antibody‐drug conjugates and antibody‐modified nanomaterials frequently suffer from low drug loading and loss of functions due to the covalent modification of the antibody. A novel and versatile strategy to prepare supramolecular nanomaterials by the coassembly of an affibody (antiHER2) and drug‐peptide amphiphiles is reported here. During the enzyme‐instructed self‐assembly process, the drug‐peptide amphiphile can coassemble with the affibody, resulting in supramolecular nanofibers in hydrogels. The drug loading in the supramolecular nanofibers is high (>30 wt%), and the stability of antiHER2 is significantly improved in the nanofibers at 37 °C (>15 d in vitro). The supramolecular nanofibers exhibit high affinity for HER2+ cancer cells and can be efficiently taken up by these cells. In a mouse tumor model, the supramolecular nanofibers abolish HER2+ NCI‐N87 tumor growth due to the good accumulation and retention of nanofibers in tumor. This study provides a novel strategy to prepare nanomedicines with high drug loading and high specificity.
A versatile strategy to prepare supramolecular nanomaterials by the coassembly of an affibody and drug‐peptide amphiphiles is reported here. The nanomaterials exhibit high drug loadings (>30 wt%), good affinity for HER2+ cancer cells, and excellent antitumor effect. This study provides a novel strategy to prepare nanomedicines with high drug loading and high specificity. |
| doi_str_mv | 10.1002/adhm.201800899 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2117821264</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2117821264</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3739-fa936f72df2db3157c106785db78239721ba9fb7c6b9635718fa9e6c313490043</originalsourceid><addsrcrecordid>eNqFkMtKAzEUQIMoVqpblxJwI0jrTdJJJsviq0J94GMdMjOJnTLTjEmH0p2f4Df6JaZUK7gxBJLFuYfLQeiQQJ8A0DNdTOo-BZICpFJuoT1KJO1RnsjtzX8AHXQQwhTi4QnhKdlFHQYMqExgD6mntvG6dpXJ20p7fKdnzpaZ8QE7iy98-_r5_vFgmnlZGDysm0kZb2WwnhV4aCPpiiWOjsabEPDo8pGe4ue2dh5fe7eYT_bRjtVVMAffbxe9XF0-n4964_vrm_PhuJczwWTPasm4FbSwtMgYSUROgIs0KTKRUiYFJZmWNhM5zyRniSBpnDA8Z4QNJMCAddHJ2tt499aaMFd1GXJTVXpmXBsUJSSaSOwR0eM_6NS1fha3ixTjAIkUIlL9NZV7F4I3VjW-rLVfKgJqVV-t6qtN_Thw9K1ts9oUG_yndQTkGljEgMt_dGp4Mbr9lX8Bfc-P3w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2136005977</pqid></control><display><type>article</type><title>Supramolecular Nanofibers of Drug‐Peptide Amphiphile and Affibody Suppress HER2+ Tumor Growth</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Liang, Chunhui ; Zhang, Lushuai ; Zhao, Wene ; Xu, Linlin ; Chen, Yaoxia ; Long, Jiafu ; Wang, Fuqiang ; Wang, Ling ; Yang, Zhimou</creator><creatorcontrib>Liang, Chunhui ; Zhang, Lushuai ; Zhao, Wene ; Xu, Linlin ; Chen, Yaoxia ; Long, Jiafu ; Wang, Fuqiang ; Wang, Ling ; Yang, Zhimou</creatorcontrib><description>Antibody‐based medicines and nanomedicines are very promising for cancer therapy due to the high specificity and efficacy of antibodies. However, antibody‐drug conjugates and antibody‐modified nanomaterials frequently suffer from low drug loading and loss of functions due to the covalent modification of the antibody. A novel and versatile strategy to prepare supramolecular nanomaterials by the coassembly of an affibody (antiHER2) and drug‐peptide amphiphiles is reported here. During the enzyme‐instructed self‐assembly process, the drug‐peptide amphiphile can coassemble with the affibody, resulting in supramolecular nanofibers in hydrogels. The drug loading in the supramolecular nanofibers is high (>30 wt%), and the stability of antiHER2 is significantly improved in the nanofibers at 37 °C (>15 d in vitro). The supramolecular nanofibers exhibit high affinity for HER2+ cancer cells and can be efficiently taken up by these cells. In a mouse tumor model, the supramolecular nanofibers abolish HER2+ NCI‐N87 tumor growth due to the good accumulation and retention of nanofibers in tumor. This study provides a novel strategy to prepare nanomedicines with high drug loading and high specificity.
A versatile strategy to prepare supramolecular nanomaterials by the coassembly of an affibody and drug‐peptide amphiphiles is reported here. The nanomaterials exhibit high drug loadings (>30 wt%), good affinity for HER2+ cancer cells, and excellent antitumor effect. This study provides a novel strategy to prepare nanomedicines with high drug loading and high specificity.</description><identifier>ISSN: 2192-2640</identifier><identifier>EISSN: 2192-2659</identifier><identifier>DOI: 10.1002/adhm.201800899</identifier><identifier>PMID: 30302950</identifier><language>eng</language><publisher>Germany: Wiley Subscription Services, Inc</publisher><subject>affibody ; Antibodies ; antitumor ; Cancer ; coassembly ; enzymes ; ErbB-2 protein ; Hydrogels ; Nanofibers ; Nanomaterials ; Nanotechnology ; Peptides ; Tumors</subject><ispartof>Advanced healthcare materials, 2018-11, Vol.7 (22), p.e1800899-n/a</ispartof><rights>2018 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim</rights><rights>2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3739-fa936f72df2db3157c106785db78239721ba9fb7c6b9635718fa9e6c313490043</citedby><cites>FETCH-LOGICAL-c3739-fa936f72df2db3157c106785db78239721ba9fb7c6b9635718fa9e6c313490043</cites><orcidid>0000-0003-2967-6920</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fadhm.201800899$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fadhm.201800899$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30302950$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Liang, Chunhui</creatorcontrib><creatorcontrib>Zhang, Lushuai</creatorcontrib><creatorcontrib>Zhao, Wene</creatorcontrib><creatorcontrib>Xu, Linlin</creatorcontrib><creatorcontrib>Chen, Yaoxia</creatorcontrib><creatorcontrib>Long, Jiafu</creatorcontrib><creatorcontrib>Wang, Fuqiang</creatorcontrib><creatorcontrib>Wang, Ling</creatorcontrib><creatorcontrib>Yang, Zhimou</creatorcontrib><title>Supramolecular Nanofibers of Drug‐Peptide Amphiphile and Affibody Suppress HER2+ Tumor Growth</title><title>Advanced healthcare materials</title><addtitle>Adv Healthc Mater</addtitle><description>Antibody‐based medicines and nanomedicines are very promising for cancer therapy due to the high specificity and efficacy of antibodies. However, antibody‐drug conjugates and antibody‐modified nanomaterials frequently suffer from low drug loading and loss of functions due to the covalent modification of the antibody. A novel and versatile strategy to prepare supramolecular nanomaterials by the coassembly of an affibody (antiHER2) and drug‐peptide amphiphiles is reported here. During the enzyme‐instructed self‐assembly process, the drug‐peptide amphiphile can coassemble with the affibody, resulting in supramolecular nanofibers in hydrogels. The drug loading in the supramolecular nanofibers is high (>30 wt%), and the stability of antiHER2 is significantly improved in the nanofibers at 37 °C (>15 d in vitro). The supramolecular nanofibers exhibit high affinity for HER2+ cancer cells and can be efficiently taken up by these cells. In a mouse tumor model, the supramolecular nanofibers abolish HER2+ NCI‐N87 tumor growth due to the good accumulation and retention of nanofibers in tumor. This study provides a novel strategy to prepare nanomedicines with high drug loading and high specificity.
A versatile strategy to prepare supramolecular nanomaterials by the coassembly of an affibody and drug‐peptide amphiphiles is reported here. The nanomaterials exhibit high drug loadings (>30 wt%), good affinity for HER2+ cancer cells, and excellent antitumor effect. This study provides a novel strategy to prepare nanomedicines with high drug loading and high specificity.</description><subject>affibody</subject><subject>Antibodies</subject><subject>antitumor</subject><subject>Cancer</subject><subject>coassembly</subject><subject>enzymes</subject><subject>ErbB-2 protein</subject><subject>Hydrogels</subject><subject>Nanofibers</subject><subject>Nanomaterials</subject><subject>Nanotechnology</subject><subject>Peptides</subject><subject>Tumors</subject><issn>2192-2640</issn><issn>2192-2659</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNqFkMtKAzEUQIMoVqpblxJwI0jrTdJJJsviq0J94GMdMjOJnTLTjEmH0p2f4Df6JaZUK7gxBJLFuYfLQeiQQJ8A0DNdTOo-BZICpFJuoT1KJO1RnsjtzX8AHXQQwhTi4QnhKdlFHQYMqExgD6mntvG6dpXJ20p7fKdnzpaZ8QE7iy98-_r5_vFgmnlZGDysm0kZb2WwnhV4aCPpiiWOjsabEPDo8pGe4ue2dh5fe7eYT_bRjtVVMAffbxe9XF0-n4964_vrm_PhuJczwWTPasm4FbSwtMgYSUROgIs0KTKRUiYFJZmWNhM5zyRniSBpnDA8Z4QNJMCAddHJ2tt499aaMFd1GXJTVXpmXBsUJSSaSOwR0eM_6NS1fha3ixTjAIkUIlL9NZV7F4I3VjW-rLVfKgJqVV-t6qtN_Thw9K1ts9oUG_yndQTkGljEgMt_dGp4Mbr9lX8Bfc-P3w</recordid><startdate>201811</startdate><enddate>201811</enddate><creator>Liang, Chunhui</creator><creator>Zhang, Lushuai</creator><creator>Zhao, Wene</creator><creator>Xu, Linlin</creator><creator>Chen, Yaoxia</creator><creator>Long, Jiafu</creator><creator>Wang, Fuqiang</creator><creator>Wang, Ling</creator><creator>Yang, Zhimou</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QF</scope><scope>7QP</scope><scope>7QQ</scope><scope>7SC</scope><scope>7SE</scope><scope>7SP</scope><scope>7SR</scope><scope>7T5</scope><scope>7TA</scope><scope>7TB</scope><scope>7TM</scope><scope>7TO</scope><scope>7U5</scope><scope>8BQ</scope><scope>8FD</scope><scope>F28</scope><scope>FR3</scope><scope>H8D</scope><scope>H8G</scope><scope>H94</scope><scope>JG9</scope><scope>JQ2</scope><scope>K9.</scope><scope>KR7</scope><scope>L7M</scope><scope>L~C</scope><scope>L~D</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-2967-6920</orcidid></search><sort><creationdate>201811</creationdate><title>Supramolecular Nanofibers of Drug‐Peptide Amphiphile and Affibody Suppress HER2+ Tumor Growth</title><author>Liang, Chunhui ; Zhang, Lushuai ; Zhao, Wene ; Xu, Linlin ; Chen, Yaoxia ; Long, Jiafu ; Wang, Fuqiang ; Wang, Ling ; Yang, Zhimou</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3739-fa936f72df2db3157c106785db78239721ba9fb7c6b9635718fa9e6c313490043</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>affibody</topic><topic>Antibodies</topic><topic>antitumor</topic><topic>Cancer</topic><topic>coassembly</topic><topic>enzymes</topic><topic>ErbB-2 protein</topic><topic>Hydrogels</topic><topic>Nanofibers</topic><topic>Nanomaterials</topic><topic>Nanotechnology</topic><topic>Peptides</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liang, Chunhui</creatorcontrib><creatorcontrib>Zhang, Lushuai</creatorcontrib><creatorcontrib>Zhao, Wene</creatorcontrib><creatorcontrib>Xu, Linlin</creatorcontrib><creatorcontrib>Chen, Yaoxia</creatorcontrib><creatorcontrib>Long, Jiafu</creatorcontrib><creatorcontrib>Wang, Fuqiang</creatorcontrib><creatorcontrib>Wang, Ling</creatorcontrib><creatorcontrib>Yang, Zhimou</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Aluminium Industry Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Ceramic Abstracts</collection><collection>Computer and Information Systems Abstracts</collection><collection>Corrosion Abstracts</collection><collection>Electronics & Communications Abstracts</collection><collection>Engineered Materials Abstracts</collection><collection>Immunology Abstracts</collection><collection>Materials Business File</collection><collection>Mechanical & Transportation Engineering Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Solid State and Superconductivity Abstracts</collection><collection>METADEX</collection><collection>Technology Research Database</collection><collection>ANTE: Abstracts in New Technology & Engineering</collection><collection>Engineering Research Database</collection><collection>Aerospace Database</collection><collection>Copper Technical Reference Library</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Materials Research Database</collection><collection>ProQuest Computer Science Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Civil Engineering Abstracts</collection><collection>Advanced Technologies Database with Aerospace</collection><collection>Computer and Information Systems Abstracts Academic</collection><collection>Computer and Information Systems Abstracts Professional</collection><collection>MEDLINE - Academic</collection><jtitle>Advanced healthcare materials</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liang, Chunhui</au><au>Zhang, Lushuai</au><au>Zhao, Wene</au><au>Xu, Linlin</au><au>Chen, Yaoxia</au><au>Long, Jiafu</au><au>Wang, Fuqiang</au><au>Wang, Ling</au><au>Yang, Zhimou</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Supramolecular Nanofibers of Drug‐Peptide Amphiphile and Affibody Suppress HER2+ Tumor Growth</atitle><jtitle>Advanced healthcare materials</jtitle><addtitle>Adv Healthc Mater</addtitle><date>2018-11</date><risdate>2018</risdate><volume>7</volume><issue>22</issue><spage>e1800899</spage><epage>n/a</epage><pages>e1800899-n/a</pages><issn>2192-2640</issn><eissn>2192-2659</eissn><abstract>Antibody‐based medicines and nanomedicines are very promising for cancer therapy due to the high specificity and efficacy of antibodies. However, antibody‐drug conjugates and antibody‐modified nanomaterials frequently suffer from low drug loading and loss of functions due to the covalent modification of the antibody. A novel and versatile strategy to prepare supramolecular nanomaterials by the coassembly of an affibody (antiHER2) and drug‐peptide amphiphiles is reported here. During the enzyme‐instructed self‐assembly process, the drug‐peptide amphiphile can coassemble with the affibody, resulting in supramolecular nanofibers in hydrogels. The drug loading in the supramolecular nanofibers is high (>30 wt%), and the stability of antiHER2 is significantly improved in the nanofibers at 37 °C (>15 d in vitro). The supramolecular nanofibers exhibit high affinity for HER2+ cancer cells and can be efficiently taken up by these cells. In a mouse tumor model, the supramolecular nanofibers abolish HER2+ NCI‐N87 tumor growth due to the good accumulation and retention of nanofibers in tumor. This study provides a novel strategy to prepare nanomedicines with high drug loading and high specificity.
A versatile strategy to prepare supramolecular nanomaterials by the coassembly of an affibody and drug‐peptide amphiphiles is reported here. The nanomaterials exhibit high drug loadings (>30 wt%), good affinity for HER2+ cancer cells, and excellent antitumor effect. This study provides a novel strategy to prepare nanomedicines with high drug loading and high specificity.</abstract><cop>Germany</cop><pub>Wiley Subscription Services, Inc</pub><pmid>30302950</pmid><doi>10.1002/adhm.201800899</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0003-2967-6920</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2192-2640 |
| ispartof | Advanced healthcare materials, 2018-11, Vol.7 (22), p.e1800899-n/a |
| issn | 2192-2640 2192-2659 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2117821264 |
| source | Wiley Online Library Journals Frontfile Complete |
| subjects | affibody Antibodies antitumor Cancer coassembly enzymes ErbB-2 protein Hydrogels Nanofibers Nanomaterials Nanotechnology Peptides Tumors |
| title | Supramolecular Nanofibers of Drug‐Peptide Amphiphile and Affibody Suppress HER2+ Tumor Growth |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T22%3A44%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Supramolecular%20Nanofibers%20of%20Drug%E2%80%90Peptide%20Amphiphile%20and%20Affibody%20Suppress%20HER2+%20Tumor%20Growth&rft.jtitle=Advanced%20healthcare%20materials&rft.au=Liang,%20Chunhui&rft.date=2018-11&rft.volume=7&rft.issue=22&rft.spage=e1800899&rft.epage=n/a&rft.pages=e1800899-n/a&rft.issn=2192-2640&rft.eissn=2192-2659&rft_id=info:doi/10.1002/adhm.201800899&rft_dat=%3Cproquest_cross%3E2117821264%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2136005977&rft_id=info:pmid/30302950&rfr_iscdi=true |